hepatic dysfunction, 2 17 graft-vs-host disease (GvHD), 22 sepsis, 4 18 21 and invasive fungal infection. 20 However, published studies have yielded conflicting results and the prognostic significance of some variables has changed in the last few years, an example being HSCT which is no longer associated with increased mortality. 3 11 20 23 The ability to identify key prognostic variables of outcome within the first few days may help clinicians recognize those patients who are most likely to benefit from ICU therapy and may allow development of treatment decision models of ICU care for these patients. The aims of this study were to re-evaluate the ICU, in-hospital, and 6 month mortality of patients admitted with haematological malignancy to a specialist cancer ICU over a 5 yr period. Secondary aims were to identify key variables prognostic of in-hospital mortality.
Methods
The Royal Marsden NHS Foundation Trust is a tertiary referral cancer centre treating over 40 000 patients a year. The ICU is a 12-bed dedicated cancer unit. ICU management consists of standard supportive care, with invasive and non-invasive mechanical ventilation using lung protective strategies, renal replacement therapy, vasopressors, and the Surviving Sepsis Campaign guidelines for the management of sepsis. 24 Haemodynamic monitoring includes the use of central venous monitoring, arterial pressure monitoring, and LIDCO TM for cardiac output measurement. The hospital does not have an emergency department, but there is a 24 h Clinical Assessment Unit where patients known to the hospital are reviewed and admitted if necessary.
After local approval from the Committee of Clinical Research to undertake the project, data were collected on all patients admitted to the ICU with haematological malignancy as a primary diagnosis or a concurrent co-morbidity over a 5 yr period (October 1, 2004 -September 30, 2009 ). The hospital information system, medical notes, and ICU charts were reviewed. Variables recorded were: patient characteristics, type of haematological malignancy, reason for ICU admission (Table 1) , HSCT (type, date, conditioning regime; Table 2 ), presence of GvHD, use of steroids, APACHE II score, number of organ failures as defined by Knaus and colleagues, 25 and type of organ support during the first 24 h of ICU admission, that is, invasive mechanical ventilation, renal replacement therapy, vasopressors, and inotropes. Laboratory data, including haemoglobin, neutropenia (defined as a neutrophil count of ,1.0×10 9 litre 21 ), platelet count, C-reactive protein, urea, creatinine, albumin, and liver function tests, were collected in the first 24 h of admission. Evidence of invasive fungal infection, defined as a positive blood culture or histological specimen, was recorded. ICU, hospital length of stay, and time in-hospital before ICU admission were noted. Patients were followed-up for 6 months from the day of ICU admission. Patients who were admitted to ICU for ,8 h were excluded from the study.
The primary outcome was ICU mortality, defined as the number of patients with haematological malignancy who died in ICU divided by the total number of patients admitted to ICU with haematological malignancy during the study period. Secondary outcomes were in-hospital and 6 month mortality defined by similar means. The plan for statistical analysis was agreed a priori, and variables in which ≥20% of data were missing were excluded from multivariate analysis. The data were analysed using Microsoft Excel and SPSS for Windows software TM . All data were treated as non-parametric. Key prognostic variables in determining in-hospital mortality were assessed using univariate (x 2 for categorical and the Mann -Whitney U for continuous data) and multivariate analysis by binary logistic regression model using a forward stepwise method. A P-value of ,0.05 was considered statistically significant.
Results
During the study period, 199 patients with haematological malignancies (HM) were admitted to the ICU, representing 5.3% of all ICU admissions (Tables 1 and 2 ). The median (P¼0.03), and invasive fungal infection (P¼0.04) ( Table 3 ).
Variables that were not predictive of in-hospital mortality were: HSCT (P¼0.19), neutropenia (P¼0.06), duration of ICU stay .5 days (P¼0.25), type of haematological malignancy (P¼0.41), and age (P¼0.51) ( Table 3 ). Multivariate analysis showed that failure of ≥2 organ systems, odds ratio (OR) 5.62 [95% confidence interval (95% CI), 2.30 -13.70), and invasive mechanical ventilation, OR 3.03 (95% CI, 1.33 -6.90), were independent predictors of in-hospital mortality (Table 4) .
Discussion
This study is one of the largest single-centre studies in the literature of ICU patients with haematological malignancy and includes a significant proportion of HSCT patients. It is unique, in that it includes contemporaneous data from a dedicated cancer ICU. Our ICU, in-hospital, and 6 month mortalities were 33.7%, 45.7% and 59.3%, respectively. A recent multi-centre study from the UK reported ICU and in-hospital mortalities of 43.1% and 59.2%, respectively, for patients admitted to ICU with haematological malignancy as a primary or secondary diagnosis 11 ( Table 5 ).
The differences in mortality observed between studies, including ours, may in part be explained by variations in case mix, admission and discharge criteria, treatment decisions, and the implementation of end-of-life decisions and the authors fully acknowledge the limitations of comparing crude mortality figures between studies. However, the lower mortality in our study may be attributable to prompt on-site access to senior haematological expertise and chemotherapy on ICU, effective triaging of patients to identify those most likely to benefit from ICU care, early admission of patients identified as being at risk of multi-organ dysfunction, to developments in radiotherapy and drug therapies, and to the high case volume seen in our ICU. There is emerging evidence that patients with HM may benefit from being managed in ICUs with higher caseloads 26 and at our institution patients with haematological malignancy account for 5.3% of all ICU admissions and 21.2% of medical ICU admissions (vs most general ICUs where patients with haematological malignancy account for only 1.5% of admissions) 11 and this may account for some of the difference. It is already a standard practice to focus the care of certain conditions (such as poly-trauma and head injuries) in specialist centres, and our work adds to the body of evidence that poses a similar question for critically ill patients with haematological malignancy. The recent UK National Confidential Inquiry in Patient Outcome and Deaths (NCEPOD) report highlighted the need for clear clinical cancer pathways, local policies for the management of neutropenic sepsis, appropriately trained staff, and specialist oncological advice to be readily available. 27 It noted that nearly half of emergency admissions after chemotherapy were cared for by general medical teams rather than oncologists and questioned whether this was appropriate. 27 The ICU management of these patients is intimately dependent upon integrated multi-professional teams of specialists working to deliver individualized care based on consensus guidelines. 5 The ability to access highly specialized integrated multi-disciplinary teams, experimental drugs, novel chemotherapeutic agents, microbiology expertise, specific diagnostic, and therapeutic therapies, including bone marrow aspiration, HSCT, and plasmapheresis in comprehensive cancer centres, are likely to have significant impact on patients' outcomes. Post-ICU rehabilitation, pastoral and psychological support, outpatient follow-up, and palliative care services specifically tailored to the needs of patients with HM and their families are an important consideration. Such resources are a persuasive argument for the early transfer of critically ill patients with haematological malignancy to specialized units. However, it may not be possible to refer all such patients on grounds that they may be too sick to be transferred or that the resources to admit them to specialist centres may not be present without substantial investments in infrastructure and staffing. Our ICU, in-hospital, and 6 month mortalities have decreased by 11% within 5 yr. Although not statistically significant, the improvements in outcome seen over time in this study and those published in the literature may be attributed to multiple factors, including the use of targeted therapies associated with less organ toxicity, 28 reduced intensity regimes and/or supportive agents in patients with multiple co-morbidities, 29 watch and wait policies in patients with stable disease, 30 development of enhanced diagnostic and therapeutic strategies, anti-fungal prophylaxis, 31 and the use of non-invasive ventilation. 32 General improvements in ICU care, including protective lung strategies for invasive mechanical ventilation, 33 goal-directed therapy, 34 the Surviving Sepsis Campaign, 24 and the expansion of critical care outreach services, have undoubtedly contributed to a reduction in mortality. Early discussion and consensus agreement between concerned parties (clinicians, patients, and their families) about the merits of ICU admission and the level of organ support that should be provided is vitally important in patients with multiple variables predictive of poor outcome. The value of a proactive, rather than reactive, approach to such decisions cannot be overemphasized. 'The ICU trial' recommended that patients should receive at least 3 days of full ICU support before appraising outcomes and making end-of-life decisions. 35 At our institution, we have proposed a treatment decision paradigm for deciding on both ICU admission and the duration of ICU therapy for haematological malignancy patients (Fig. 1) . We try to dissuade ICU admission in patients with poor functional status, serious co-morbidities, and progressive disease with a life expectancy of only a few weeks. Patients with relapsed or failed treatment, disease unresponsive to therapy, and/or successive failure of ≥2 organ systems, while not precluding ICU admission, require serious evaluation as to whether ICU admission can be justified. Such patients may be eligible for a 'short trial of ICU therapy', and this may include chemotherapy if appropriate. 35 Undoubtedly, the decision as to whether to treat these patients on ICU remains difficult and needs evaluation on a patient-by-patient basis. A prospective evaluation of the outcome of cancer patients referred for ICU admission reported that 21% of patients considered 'too well' for ICU admission died before hospital discharge and that 26% of the patients considered 'too sick' for ICU admission went on to survive. 36 In this study, variables that were not predictive of outcome, which were in keeping with other published studies, were type of malignancy, 20 37 age, 6 14 16 and gender. 2 6 11 21 38 Neutropenia, APACHE II score, or transplant status were not predictive of outcome in contrast to published studies. Neutropenia was previously shown to be an independent risk factor for increased mortality in ICU patients with haematological malignancy. 6 16 Some studies have not supported this finding. 8 11 19 21 Scoring systems such as APACHE II have been of variable use in predicting mortality. Some studies have found it predictive, 8 11 16 while others have found it to underestimate mortality. 3 14 Other scoring systems that have been evaluated include the ICNARC model, 11 Sequential
Organ Failure Assessment, 16 18 and SAPS II.
2 4 8 11 16 18 19 Unfortunately, none is specific for predicting mortality in patients with HM. Vasopressors, 5 6 8 18 23 renal replacement 12 The early use of non-invasive ventilation (NIV) has been advocated as it reduces the necessity for tracheal intubation 39 and ventilator-associated lung injury. 7 After HSCT, in-hospital mortality was 51.2%. Other studies have reported in-hospital mortality figures between 54% and 96%. 12 40 Transplant status was not found to be predictive of outcome in this study and other recently published studies. 6 7 17 23 This may reflect advances in conditioning regimes, use of reduced intensity regimes in patients with previous transplant or co-morbidities, targeted therapies with less organ toxicity, careful patient selection, advances in pre-and post-transplant procedures such as routine use of anti-microbial prophylaxis, and granulocyte colony-stimulating factor. However, for certain patients who have been in receipt of HSCT, the outcome remains poor, particularly for those who are invasively ventilated, 12 13 have resistant GvHD 13 14 or have multiorgan failure. 13 There were a number of limitations for this study. First, this is a retrospective single-centre study. However, it analyses 5 yr of data from one of the largest comprehensive cancer centres in Europe. Secondly, it is difficult to compare crude mortality from different studies and benchmark ICUs because of the variations in case mix, ICU admission, and discharge criteria, intubation rates, and end-of-life decisionmaking practices before ICU admission. Thirdly, we were only able to categorize patients into those receiving invasive mechanical ventilation, supplementary oxygen, and/or NIV and therefore were unable to provide specific data on patients receiving NIV. Finally, our local treatment decision paradigm of ICU care is not applicable to all institutions and is yet to be validated, but at our institution, it helps to clarify the decision-making process with regard to these complex patients.
Future studies should focus on validation of these treatment decision paradigms of ICU care and the cost implications and effectiveness of such models of care. Ascertaining key predictors of in-hospital mortality at 48-72 h rather than on ICU admission, long-term outcomes, and post-ICU quality of life for haemato-oncology patients are also important questions that deserve further exploration.
In conclusion, over the last decade, studies discussing the poor prognosis for haematological malignancy patients admitted to the ICU have slowly been replaced with more optimism as more data demonstrating improved outcomes have emerged. Our data would appear to support this assertion. Invasive mechanical ventilation and ≥2 organ failures were the only variables independently associated with in-hospital mortality. Traditional variables that were previously associated with increased in-hospital mortality such as age, neutropenia, transplantation status, and APACHE II score no longer appear to be predictive.
